Refining endpoints in brain tumor clinical trials
As targeted therapies advance treatment for brain tumors, standard clinical trial endpoints of survival, progression free survival and radiographic response have become insufficient to capture clinical benefit. Brain cancer is a malignancy with neurodegenerative features. In this setting prolongation of life and/or radiographic stability are less clinically meaningful if neurocognitive function substantially declines. Hence evaluation of new therapeutic strategies should routinely include periodic assessment of neurocognitive function.
KeywordsBrain cancer Clinical trials Neurocognitive function
Conflict of interest statement
The authors declare that they have no conflict of interest.
- 3.Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1943–1972Google Scholar
- 10.Wolfson AH, Bae K, Komaki R et al (2011) Primary analysis of a phase II randomized trial radiation therapy oncology group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. Int J Radiat Oncol Biol Phys 81:77–84PubMedCrossRefGoogle Scholar
- 14.Benton AL, KdeS Hamsher (1989) Multilingual aphasia examination. AJA Associates, Iowa CityGoogle Scholar
- 15.Lezak MD, Howieson DB, Loring DW (2004) Neuropsychological assessment. Oxford University Press, New YorkGoogle Scholar